OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

OpenAI CEO Sam Altman will brief U.S. officials on super-agents—AI systems set to revolutionize software development, finance, and event planning.

OpenAI CEO Sam Altman is reportedly scheduled to meet with officials from the Trump administration on Jan. 30. OpenAI is preparing to release a new

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as saying that Sam Altman is participating in the investment.